“And one has to wonder, again, if all the money
Post# of 36536
(Total Views: 253)
Posted On: 01/28/2020 9:48:31 AM
Re: SeekingAlfa #11472
“And one has to wonder, again, if all the money being paid for the expensive CAR-T technologies won't be challenged by the peptide technology of Generex's AE37. CAR-T might turn out to be an expensive fad. “
That’s not quite how it works. If anything we will see NGIO also become involved in CAR-T tech, as they were just about to with the merger with Kiromic. Dr von Hofe is now in that space a Pres of AppyImmune. With his dual Pres roles can he help form a collaboration? Perhaps the tech can compliment each other.
That’s not quite how it works. If anything we will see NGIO also become involved in CAR-T tech, as they were just about to with the merger with Kiromic. Dr von Hofe is now in that space a Pres of AppyImmune. With his dual Pres roles can he help form a collaboration? Perhaps the tech can compliment each other.
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼